Amid Gilead Sciences' flagging sales, HIV med Biktarvy has been a rare shining light with growth nearly quadrupling in the last year. Hoping to capitalize on its next-gen HIV portfolio's success, ...

DUBLIN--(BUSINESS WIRE)--The "Biktarvy - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Biktarvy - Drug Insight, 2019 report provides comprehensive information of the ...

The Food and Drug Administration has given Gilead the green light for a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for ...

Gilead Sciences Inc.'s drug Biktarvy has been approved for the treatment of HIV-1 in China, the company said Friday. The China National Medical Products Administration approved the drug as a treatment ...

Gilead Sciences has received permission from the Food and Drug Administration for an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy (bictegravir 50 ...

Gilead Sciences, Inc. GILD presented a series of data at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. The company announced results from two studies evaluating ...

The US Food and Drug Administration (FDA) has approved an expanded indication of the antiretroviral medication Biktarvy for younger children living with HIV. The new lower dose is approved for ...

New HIV drug Biktarvy is supposed to be Gilead's "Mount Everest." But the biotech could need need more mountains. The big biotech's latest quarterly update, announced last week, didn't convince ...

Gilead Sciences, the manufacturer of multiple pharmaceuticals, including HIV medications Biktarvy and Descovy, has issued a warning that it has become aware of counterfeit versions of these drugs ...

While Gilead saw high demand for several of its top products in the first quarter, a $2.7 billion write-down on its cancer efforts put a big dent in earnings. Gilead's HIV combo med Biktarvy and COVID ...

Please provide your email address to receive an email when new articles are posted on . Gilead Sciences said the FDA has approved a new low-dose tablet form of its HIV drug Biktarvy for pediatric ...

Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain experienced by participants taking Dovato ...